Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade D 10.17 4.85% 0.47
CCXI closed up 4.85 percent on Friday, November 16, 2018, on 78 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CCXI trend table...

Date Alert Name Type % Chg
Nov 16 Lower Bollinger Band Walk Weakness 0.00%
Nov 16 Multiple of Ten Bullish Other 0.00%
Nov 16 Wide Bands Range Expansion 0.00%
Nov 16 Oversold Stochastic Weakness 0.00%
Nov 15 Slingshot Bearish Bearish Swing Setup 4.85%
Nov 15 Bullish Engulfing Bullish 4.85%
Nov 15 Stochastic Buy Signal Bullish 4.85%
Nov 15 Lower Bollinger Band Walk Weakness 4.85%
Nov 15 Wide Bands Range Expansion 4.85%
Nov 15 Lower Bollinger Band Touch Weakness 4.85%

Older signals for CCXI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Is CCXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 15.08
52 Week Low 5.42
Average Volume 252,207
200-Day Moving Average 11.6877
50-Day Moving Average 11.1645
20-Day Moving Average 10.763
10-Day Moving Average 10.465
Average True Range 0.7193
ADX 19.22
+DI 19.9428
-DI 28.2578
Chandelier Exit (Long, 3 ATRs ) 9.9121
Chandelier Exit (Short, 3 ATRs ) 11.2279
Upper Bollinger Band 12.4599
Lower Bollinger Band 9.0661
Percent B (%b) 0.33
BandWidth 31.532101
MACD Line -0.4069
MACD Signal Line -0.2558
MACD Histogram -0.1511
Fundamentals Value
Market Cap 495.34 Million
Num Shares 48.7 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -16.40
Price-to-Sales 12.42
Price-to-Book 7.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.13
Resistance 3 (R3) 11.07 10.70 10.97
Resistance 2 (R2) 10.70 10.45 10.73 10.92
Resistance 1 (R1) 10.43 10.30 10.57 10.49 10.86
Pivot Point 10.06 10.06 10.12 10.09 10.06
Support 1 (S1) 9.79 9.81 9.93 9.85 9.48
Support 2 (S2) 9.42 9.66 9.45 9.42
Support 3 (S3) 9.15 9.42 9.37
Support 4 (S4) 9.21